Aurinia Pharmaceuticals Inc. (AUPH) has a MoatMap StockRank of 98/100 based on Quality (81/100), Value (53/100), and Momentum (60/100) factor scores. The current signal is STRONG BUY. Aurinia Pharmaceuticals, a Canadian biotech company, fits the 'Healthcare Technology & Resilience' theme as a pharmaceutical/biotech company with a 'robust R&D pipeline'. The non-discretionary demand for innovative treatments and the continuous advancements in healthcare technology create a long-term tailwind. However, biotech investment, especially for companies heavily reliant on R&D, inherently carries high risks from clinical trial failures, regulatory hurdles, and intense competition, making it less of a classic 'quality compounder' and more of a binary outcome investment.
Aurinia Pharmaceuticals Inc. is a Canadian pharmaceutical company primarily focused on developing and commercializing therapies for autoimmune diseases. Its competitive moat is centered around LUPKYNIS (voclosporin), a proprietary drug approved for lupus nephritis, addressing a high unmet medical need and offering a significant market opportunity. Aurinia operates as a commercial-stage biotech, dedicated to expanding the market presence of its specialized therapeutic.
| Price | $15.22 |
| Market Cap | $2.0B |
| P/E (TTM) | 7.20 |
| P/E (Forward) | 13.91 |
| Price/Book | 3.58 |
| Return on Equity | 65.0% |
| Return on Invested Capital | 18.0% |
| Debt/Equity | 12.09 |
| Gross Margin | 78.3% |
| Operating Margin | 53.3% |
| Revenue Growth | 24.4% |
| Free Cash Flow | $125M |
Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry, part of the Healthcare sector (Canada).